Indication

In combination with axitinib, is indicated for the first-line treatment of advanced renal cell carcinoma (RCC) in adults.

Medicine details

Medicine name:
pembrolizumab (Keytruda)
SMC ID:
SMC2247
Pharmaceutical company
Merck Sharp & Dohme Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
TBC
SMC meeting date:
TBC
Patient group submission deadline:
03 February 2020